Omnipod 5 Automated Insulin Delivery System is Now FDA Cleared for People with Type 2 Diabetes Page 1

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with the Omnipod brand of products, today announced that its breakthrough Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use in people with type 2 diabetes (ages 18 and older) in the U.S., making it the first and only AID system cleared by the FDA to treat both type 1 and type 2 diabetes.

“Today’s announcement is a significant milestone in delivering easy-to-use, patient-centric technology for the treatment of type 2 diabetes,” said Jim Hollingshead, President and Chief Executive Officer of Insulet. “Insulet is paving the way for these individuals to achieve better health outcomes while living with greater confidence and freedom through the breakthrough benefits of tubeless Pod therapy. Omnipod 5 sets a new standard in diabetes management and we are excited about the opportunity to make a lasting impact on the insulin-dependent type 2 diabetes community.”